Selank - 5MG
About Selank - 5MG
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a metabolically stabilized analog of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). The parent sequence is extended at the C-terminus with Pro-Gly-Pro to increase resistance to enzymatic breakdown. Selank is catalogued in PubChem under CID 11765600 and CAS 129954-34-3; it is sometimes referred to as TP-7.
In the research literature Selank has been studied primarily as a peptide anxiolytic and nootropic. Reported mechanisms center on modulation of GABAergic neurotransmission-gene expression, effects on monoamine and neurotrophin systems, and immunomodulatory activity inherited from its tuftsin origin. Notably, Selank is described as producing anxiolytic-type effects in models without directly binding GABA receptors. This material is supplied strictly for laboratory research and is not intended for human or animal use.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Handling and Storage Tips:
Keep peptides cold and away from light once received.
For short-term use (day s to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
FDA Disclosure & Intended Use:
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Specifications
- MaterialSelank - 5MG
- Also searched asTP-7
- Research AreaCognitive Research
- Presentation—
- CAS Number129954-34-3
- Molecular FormulaC33H57N11O9
- Molecular Weight751.9 g/mol
- TypeSynthetic heptapeptide
- Receptor / TargetGABAergic system / tuftsin (proposed); no direct GABA-receptor binding
- PubChem CID11765600 →
Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Experimental studies report that Selank administration alters the expression of numerous genes involved in GABAergic neurotransmission in rodent frontal cortex within about one hour of dosing, and comparative clinical-research literature has described its anxiolytic magnitude as broadly comparable to the benzodiazepine medazepam while additionally showing antiasthenic and mild psychostimulant characteristics. Unlike benzodiazepines, it is reported not to bind GABA receptors directly.
These results originate from in-vitro assays, animal models, and investigational clinical research reported largely in the Russian-language literature; they characterize the compound in research contexts and are not offered as evidence of clinical efficacy or safety for general use.
Selank was developed jointly by the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Research Institute of Pharmacology as a stabilized analog of tuftsin, extending the natural Thr-Lys-Pro-Arg tetrapeptide with Pro-Gly-Pro. It has since served as a widely cited peptide anxiolytic tool compound, also appearing under the designation TP-7.
- Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
- Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2015 (PMC4757669).
- Volkova A, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89.
- PubChem Compound Summary for CID 11765600, Selank. National Center for Biotechnology Information.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Cognitive Research materials
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
